Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shimadzu ( (JP:7701) ) has provided an announcement.
Shimadzu reported consolidated net sales of ¥560.7 billion for the fiscal year ended March 31, 2026, up 4% year on year, with operating profit rising 2.8% to ¥73.7 billion and profit attributable to owners of parent increasing 12.5% to ¥60.5 billion. Improved ordinary profit, stronger comprehensive income and higher cash and cash equivalents lifted the equity-to-asset ratio to 76.6%, supporting a higher annual dividend of ¥69 per share and underscoring a solid balance sheet.
Operating cash flow reached ¥54.7 billion while investing and financing outflows declined versus the prior year, indicating disciplined capital allocation and a more conservative financing stance. For the year ending March 31, 2027, Shimadzu forecasts modest sales and operating profit growth but expects lower ordinary profit and net income, signaling potential margin pressure or higher non-operating costs even as it plans a slight increase in annual dividends to ¥70 per share.
The most recent analyst rating on (JP:7701) stock is a Buy with a Yen4400.00 price target. To see the full list of analyst forecasts on Shimadzu stock, see the JP:7701 Stock Forecast page.
More about Shimadzu
Shimadzu Corporation is a Japan-based manufacturer of analytical and measuring instruments, medical systems and industrial equipment, listed on the Tokyo Stock Exchange under code 7701. The company focuses on global demand for precision testing and diagnostic technologies, serving sectors such as healthcare, pharmaceuticals, materials, and industrial quality control.
Average Trading Volume: 1,218,187
Technical Sentiment Signal: Sell
Current Market Cap: Yen1130.3B
For an in-depth examination of 7701 stock, go to TipRanks’ Overview page.